Prothena Corporation

Understanding the scientific aspects of #AlzheimersDisease is essential for recognizing its significant impact on those impacted by this disease. The Alzheimer's Association® has resources available to help patients and families enhance their understanding behind the science of this disease. Learn more: https://bit.ly/3VSSQj7

We’re proud to be a sponsor of the first International AL Amyloidosis Meeting in Brussels today! Hosted by the Amyloidosis Alliance, this two-day event will focus on managing complications of #amyloidosis and fostering collaboration between patients and medical professionals. Learn more about the event here: https://bit.ly/3zrVvc2

We stand alongside the #Alzheimers community in celebrating today’s FDA approval of a new therapy targeting amyloid beta (Aβ). This milestone marks continued progress for patients, families, and caregivers. At Prothena, we continue working to pioneer the next generation of Aβ targeting treatments with the Alzheimer's disease patient in mind.

Collaborative partnerships are fundamental in driving innovation. Our CEO, Gene Kinney, had an insightful conversation with PharmaVoice about our ongoing R&D initiatives with Bristol Myers Squibb, part of a notable comeback across the industry in the central nervous system (CNS) therapeutic area. Be sure to read more about our journey towards transformative treatments: bit.ly/3zlE0Ke

As Alzheimer’s & Brain Awareness Month concludes, raising awareness is crucial for educating and mobilizing support for affected individuals and their families. Today, Our Sr. Medical Director, Cheri Osteen shares the importance of highlighting these unmet needs of patients.    Discover our approach to advancing treatment options for neurodegenerative diseases like #Alzheimers: https://bit.ly/3VZwZru #ENDALZ

Today we share our support for #TheLongestDay. In honor of this important day, we had the privilege of speaking with LuPita, who has been living with #dementia since 2016. Deeply driven by our mission to make a difference in the lives of patients affected by #AlzheimersDisease, we believe that hearing firsthand experiences like LuPita's is crucial for raising awareness and understanding the realities of this condition.  Be sure to listen to her full story here: https://bit.ly/3RAsyAK #ENDALZ

This past weekend, many innovative and informative discussions emerged at the European Hematology Association (EHA) #EHA2024, supporting our mission in advancing treatment options for patients living with AL #amyloidosis.     Learn more on how we aim to approach this hematologic disorder by visiting our pipeline: https://bit.ly/45sSPGQ

Our CEO, Gene Kinney, recently sat down with Healio to discuss our ongoing R&D efforts in diseases caused by protein dysregulation, including developments in #Alzheimers disease, AL #amyloidosis, and our partnership with Bristol Myers Squibb. Be sure to read the Q&A here: https://bit.ly/4cksRHN

#EHA2024 is just a few days away and we look forward to connecting with the #amyloidosis community in Madrid, Spain. Make sure to stop by our symposium on Thursday, June 13, as we discuss the patient journey from before diagnosis through treatment for those living with AL amyloidosis.    Learn more about the symposium here: https://bit.ly/3yYgenu

Today’s unanimous and positive FDA Peripheral and Central Nervous System Drugs Advisory Committee vote is another step forward for the #Alzheimers disease community. As patients, families and caregivers continue to struggle with ongoing care and new #Alzheimers diagnoses, we’re working tirelessly to innovate and develop the next generation of #AlzheimersDisease treatments with the patient experience top of mind.